LivaNova PLC (NASDAQ:LIVN) Short Interest Update

LivaNova PLC (NASDAQ:LIVN) was the recipient of a large decline in short interest in the month of February. As of February 28th, there was short interest totalling 1,580,000 shares, a decline of 18.6% from the February 13th total of 1,940,000 shares. Currently, 2.9% of the company’s shares are sold short. Based on an average trading volume of 613,400 shares, the short-interest ratio is presently 2.6 days.

LivaNova Stock Down 2.4 %

NASDAQ:LIVN traded down $1.00 on Tuesday, hitting $40.41. 642,560 shares of the company’s stock were exchanged, compared to its average volume of 600,837. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. The firm has a 50-day moving average price of $45.88 and a 200-day moving average price of $49.01. The company has a market cap of $2.20 billion, a P/E ratio of 96.21 and a beta of 1.10. LivaNova has a 52 week low of $36.85 and a 52 week high of $64.48.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the company. Wolfe Research downgraded LivaNova from an “outperform” rating to a “peer perform” rating in a research note on Wednesday, February 26th. Mizuho lowered their target price on shares of LivaNova from $70.00 to $60.00 and set an “outperform” rating for the company in a research note on Wednesday, February 26th. The Goldman Sachs Group reduced their price target on shares of LivaNova from $64.00 to $55.00 and set a “buy” rating on the stock in a research report on Monday, March 3rd. StockNews.com downgraded LivaNova from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 26th. Finally, Stifel Nicolaus cut their price objective on LivaNova from $72.00 to $60.00 and set a “buy” rating on the stock in a report on Wednesday, February 26th. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $61.17.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in LIVN. Russell Investments Group Ltd. lifted its stake in LivaNova by 17.1% in the fourth quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company’s stock valued at $70,000 after acquiring an additional 219 shares during the last quarter. Sterling Capital Management LLC raised its stake in LivaNova by 800.6% in the fourth quarter. Sterling Capital Management LLC now owns 1,621 shares of the company’s stock valued at $75,000 after purchasing an additional 1,441 shares in the last quarter. Central Pacific Bank Trust Division boosted its stake in LivaNova by 21.2% in the fourth quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company’s stock valued at $191,000 after buying an additional 720 shares in the last quarter. Captrust Financial Advisors acquired a new position in LivaNova during the third quarter worth about $217,000. Finally, Sanctuary Advisors LLC bought a new position in LivaNova in the 3rd quarter valued at approximately $219,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.